Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer

BASF Pharma Solutions introduces premium services to its VPAs digital services platform

Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports

FDA approves only vaccine Penbraya for treatment of meningococcal disease in adolescents

The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease

Allergan’s conclave on World Sight Day spotlights eyecare's crucial role in workplace

India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness

Veramed acquires Clinical Trial Data Services

Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product.

Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments

Increased capability to produce medicines for challenging diseases including cancer

Cambrex completes US$38 million capacity expansion in High Point, North Carolina